In H22 tumor-bearing mice, STRGD inhibited telomerase activity and reduced the number of CD4+CD25+ regulatory T cells to inhibit tumor growth and increase body weight, thus improving the general condition of the mice [22]. The gene discussed is CD4; the disease is neoplasm.